Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: the TAILORx trial

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00310180?term=PACCT-1&rank=1

2. Intervention

   Anastrozole

3. Intervention

   Exemestane

4. Intervention

   Letrozole

5. Intervention

   Tamoxifen citrate

6. Additional Topic(s)

   Combined antineoplastic chemotherapy

7. Additional Topic(s)

   Hormone therapy

8. Additional Topic(s)

   Oncotype DX

9. Resource Description

   New tests may provide information about which patients are more likely to benefit from chemotherapy. This randomized phase III trial is trying to find out the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25.

10. Contact

    Berenberg, Jeffrey

11. PI

    Berenberg, Jeffrey

12. Topic

    breast cancer

13. Study Population

    Women 18 to 75 years with histologically confirmed adenocarcinoma of the breast

14. Funded by

    Cancer Trials Support Unit

15. Phase

    Phase 3 clinical trial

16. Performed by

    Clinical Protocol & Data Management Shared Resource